Skye preparing to start Phase 2a glaucoma clinical trial in Q3 San Diego, California–(Newsfile Corp. – July 13, 2023) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”...
San Diego, California–(Newsfile Corp. – July 6, 2023) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid...
Skye completes dosing of final cohort of healthy volunteers in study of first-and-only-in-class proprietary cannabinoid derivative San Diego, California–(Newsfile Corp. – June 12, 2023) – Skye...
San Diego, California–(Newsfile Corp. – June 5, 2023) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid...
Skye plans to complete enrollment of Phase 1 study in June San Diego, California–(Newsfile Corp. – June 2, 2023) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”...
Skye advances multiple ascending dose arm of SBI-100 Ophthalmic Emulsion trial San Diego, California–(Newsfile Corp. – May 17, 2023) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”...
San Diego, California–(Newsfile Corp. – May 15, 2023) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid...
Skye progresses to multiple ascending dose arm of SBI-100 Ophthalmic Emulsion trial after completing single ascending dose arm P1 dosing of novel cannabinoid derivative planned for...
Enrollment started for multiple ascending dose arm of Phase 1 study San Diego, California–(Newsfile Corp. – April 4, 2023) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”...
San Diego, California–(Newsfile Corp. – April 3, 2023) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid...